Skip to main content

Pmv Pharmaceuticals Inc (NASDAQ: PMVP) — Company Overview, News & Financial Data

Pmv Pharmaceuticals Inc logo
PMVP Pmv Pharmaceuticals Inc
Pmv Pharmaceuticals Inc primary media
Company profile

Pmv Pharmaceuticals Inc

PMV Pharmaceuticals (NASDAQ:PMVP) is dedicated to the discovery and development of precision medicines for cancer treatment. With a focus on leveraging the power of p53, the body's natural tumor suppressor protein, Pmv aims to unlock new therapeutic options for patients. The company's projects primarily revolve around creating small molecule therapies designed to restore the normal function of mutant p53 proteins. Their objective is to advance these groundbreaking treatments through clinical trials with the ultimate goal of offering new hope to individuals battling cancer. This pursuit not only reflects Pmv's commitment to innovation in oncology but also underscores their dedication to improving patient outcomes through scientific excellence.

Snapshot

Public USOwnership
2013Year founded
63Employees
New Jersey, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
United States

Products and/or services of Pmv Pharmaceuticals Inc

  • PC14586, a small molecule reactivator of p53 Y220C mutant.
  • Research in targeted therapies for cancer with p53 mutations.
  • Pipeline development for small molecule therapeutics in oncology.
  • Advancements in precision medicine for cancer treatment.
  • Collaborations with leading biotech firms to enhance drug discovery.
  • Services in drug development and clinical trial support for cancer therapies.

Pmv Pharmaceuticals Inc executive team

  • David H. MackCo-Founder, CEO, President & Director
  • Arnold J. LevineCo-Founder, Independent Director & Member of Scientific Advisory Board
  • Robert TicktinGeneral Counsel, COO & Company Secretary
  • Deepika JalotaChief Development Officer
  • Michael CarulliCFO & Principal Financial & Accounting Officer
  • Tim SmithSenior VP and Head of Corporate Development & Investor Relations

Key financials

Reported results for Pmv Pharmaceuticals Inc, in USD.

Market cap
103.5M
Revenue (TTM)
0
P/E ratio
—
EPS (diluted, TTM)
-1.4
Dividend yield
—
Profit margin
0.0%
Pmv Pharmaceuticals Inc annual revenue and income
Fiscal year endRevenueOperating incomeNet income
0-86.2M-77.7M
0-85.4M-58.7M
0-80.1M-69M
0-77M-73.3M